CTXR: LYMPHIR commercial growth catalyst trading at around 3x its average volume

​

Citius Pharmaceuticals recently announced strong commercial progress for LYMPHIR, its FDA-approved cancer treatment for relapsed/refractory cutaneous T-cell lymphoma. New institutions ordering LYMPHIR increased 78% quarter-over-quarter, while institutional vial orders increased 31%. LYMPHIR is now available in 42 institutions, and the company estimates the CTCL market opportunity exceeds $400M.

CTXR currently has a $14.10M market cap with 4.98M shares short, representing 18.48% of the float. Fintel shows 7.07 days to cover and a 37.67% borrow rate. Recent volume reached 1.54M shares, around 3x its average volume of 494.5K. With a small market cap, growing commercial adoption, and a large short position, continued positive LYMPHIR updates could create additional buying pressure and force shorts to cover.

https://www.prnewswire.com/news-releases/citius-oncology-reports-strong-commercial-momentum-for-its-cancer-treatment-302843701.html

NDA DD